Therapy (HBV)

IFN-(alpha) Does Not Promote Autoantibody Development

Published in Hepatitis Weekly, October 7th, 1996

Autoantibodies are common in hepatitis B virus infection but their prevalence is not influenced by interferon alpha, according to a report from the United Kingdom.

Interferon alfa (IFN-(alpha)) is the most successful drug currently in use for the treatment of liver disease caused by chronic hepatitis infection. Its most common side effect is an influenza-like syndrome that usually disappears after the first few treatment doses. Other possible toxicities, however, such as the induction of autoimmunity, are more dangerous.

"Autoimmune phenomena ranging from appearance of tissue autoantibodies to overt autoimmune disease, such as thyroiditis, systemic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1996-10-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry